Condition: Arthritis, Rheumatoid
Interventions: Biological: GSK3196165; Drug: Tofacitinib; Drug: Placebo to GSK3196165; Drug: Placebo to Tofacitinib; Drug: csDMARDs
Sponsors: GlaxoSmithKline; IQVIA
Not yet recruiting
ClinicalTrials.gov: Musculoskeletal | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
June 3, 2019ClinicalTrials.govComments OffMusculoskeletalActive | Antirheumatic | Arthritis | Conventional | cs/Biologic | Disease | DMARDs | Drugs | Efficacy | GSK3196165 | Inadequate | Moderately | Modifying | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Synthetic | Tofacitinib | Versus
Comments
